JP2025516639A5 - - Google Patents
Info
- Publication number
- JP2025516639A5 JP2025516639A5 JP2024566533A JP2024566533A JP2025516639A5 JP 2025516639 A5 JP2025516639 A5 JP 2025516639A5 JP 2024566533 A JP2024566533 A JP 2024566533A JP 2024566533 A JP2024566533 A JP 2024566533A JP 2025516639 A5 JP2025516639 A5 JP 2025516639A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- promoter
- mir
- sequence
- aimp2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341798P | 2022-05-13 | 2022-05-13 | |
| US63/341,798 | 2022-05-13 | ||
| PCT/IB2023/054956 WO2023218430A1 (en) | 2022-05-13 | 2023-05-13 | Methods of treating retinal degenerative diseases using aimp2-dx2 and optionally a target sequence for mir‑142 and compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516639A JP2025516639A (ja) | 2025-05-30 |
| JP2025516639A5 true JP2025516639A5 (enExample) | 2026-05-21 |
Family
ID=88729819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566533A Pending JP2025516639A (ja) | 2022-05-13 | 2023-05-13 | ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２に対する標的配列を使用して網膜変性疾患を処置する方法ならびにその組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250281573A1 (enExample) |
| EP (1) | EP4522226A4 (enExample) |
| JP (1) | JP2025516639A (enExample) |
| KR (1) | KR20250021321A (enExample) |
| CN (1) | CN119343154A (enExample) |
| WO (1) | WO2023218430A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4221760A4 (en) * | 2020-09-30 | 2025-08-13 | Generoath Co Ltd | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR MIR-142 AND RELATED COMPOSITIONS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459529B2 (en) * | 2004-11-24 | 2008-12-02 | Seoul National University Industry Foundation | AIMP2-DX2 and its uses |
| DK2002003T3 (en) * | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
| CN107184594A (zh) * | 2017-06-02 | 2017-09-22 | 青岛大学 | miR‑142‑3p用于预防和/或治疗心脏疾病的组合物及应用 |
| KR102248420B1 (ko) * | 2019-03-15 | 2021-05-06 | 주식회사 제너로스 | miR-142-3p의 표적 서열을 포함하는 재조합 벡터 |
| KR20220035693A (ko) * | 2020-09-14 | 2022-03-22 | 주식회사 제너로스 | 표적화된 유전자 전달을 위한 아데노-부속 바이러스 벡터 |
| JP2023541168A (ja) * | 2020-09-14 | 2023-09-28 | ジェネロス カンパニー， リミテッド | 改良された生着可能性を有する幹細胞を調製するための方法 |
| KR102626543B1 (ko) * | 2020-09-14 | 2024-01-23 | 주식회사 제너로스 | AIMP2-DX2 및 miR-142의 표적 핵산을 포함하는 재조합 벡터 |
| MA71714A (fr) * | 2020-09-30 | 2025-05-30 | Generoath Co., Ltd. | Méthodes de traitement de maladies neuronales à l'aide d'aimp2-dx2 et éventuellement d'une séquence cible de mir-142 et compositions associées |
| EP4221760A4 (en) * | 2020-09-30 | 2025-08-13 | Generoath Co Ltd | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR MIR-142 AND RELATED COMPOSITIONS |
-
2023
- 2023-05-13 CN CN202380039975.2A patent/CN119343154A/zh active Pending
- 2023-05-13 WO PCT/IB2023/054956 patent/WO2023218430A1/en not_active Ceased
- 2023-05-13 KR KR1020247041223A patent/KR20250021321A/ko active Pending
- 2023-05-13 JP JP2024566533A patent/JP2025516639A/ja active Pending
- 2023-05-13 EP EP23803147.0A patent/EP4522226A4/en active Pending
- 2023-05-13 US US18/858,540 patent/US20250281573A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023544142A5 (enExample) | ||
| US10568972B2 (en) | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions | |
| US10369232B2 (en) | Allele selective gene editing and uses thereof | |
| JP2023544141A5 (enExample) | ||
| Ahlers et al. | Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes | |
| JP2022115876A5 (enExample) | ||
| Chamberlain et al. | Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines | |
| JPH09509060A (ja) | 遺伝子治療に使用できる宿主 − ベクタ系 | |
| US20200085852A1 (en) | Epidermal mrna vaccine | |
| JP2019501671A5 (enExample) | ||
| JP2022530833A5 (enExample) | ||
| JP7291423B2 (ja) | ＡＩＭＰ２－ＤＸ２およびｍｉＲ－１４２の標的核酸を含むベクター、ならびにその使用 | |
| JP2023545229A5 (enExample) | ||
| JP2023536570A5 (enExample) | ||
| US20030082150A1 (en) | Recombinant adenoviral vectors for human tumour gene therapy | |
| JP2022512667A5 (enExample) | ||
| CZ20011521A3 (cs) | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek | |
| TWI905155B (zh) | 包含 il-2蛋白及cd80蛋白片段或其變異體的融合蛋白及其用途 | |
| KR102500873B1 (ko) | 자연살해세포 특이적 CRISPR/Cas 시스템을 위한 융합 단백질 및 이의 용도 | |
| JP2004505113A (ja) | 単純疱疹ウイルス糖蛋白質ｄを用いた組成物及びそれを用いて免疫応答を抑制する方法 | |
| JP2026506536A (ja) | 核酸ベースのがんワクチンおよびその方法 | |
| KR102626543B1 (ko) | AIMP2-DX2 및 miR-142의 표적 핵산을 포함하는 재조합 벡터 | |
| JP2020516673A5 (enExample) | ||
| CN102787119A (zh) | 治疗和/或预防病毒感染的产品及方法 | |
| WO2005037218A2 (en) | Lentiviral vector delivery of il-21 for treatment of cancer |